Newly Characterized Protein May Protect Spinal Discs From Age-related Damage
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

University of Utah researchers report that the protein BLST is associated with healthier spinal discs and may help limit DNA damage and cellular aging. Experiments in human disc cells and rodent models point to a possible research target for age-related back pain, but no treatment has been shown safe or effective in people.

University of Utah researchers have characterized BLST, also known as ZNF865, as a protein that may help protect spinal disc cells from DNA damage and age-related dysfunction. In a study published in Aging Cell, changing BLST levels affected human disc cells and rodent models, offering a possible avenue for future back-pain research—not an established treatment for people.

For listenersOffer from Amazon

Turn quiet afternoons into listening time

  • Thousands of audiobooks, podcasts and originals
  • Listen on your phone, tablet or Echo — also offline
  • Cancel anytime
Try Audible free Free trial for new members
As an affiliate, we earn on qualifying purchases.

The team used CRISPR gene editing to investigate BLST in human spinal disc cells and in mouse and rat models. The researchers reported that BLST levels were lower in older and damaged discs. Restoring BLST production in human disc cells reduced signs of cellular aging and DNA damage, according to the study summary.

In the animal experiments, reducing BLST activity was associated with disc degeneration and pain-related behaviors. The results suggest the protein helps maintain disc tissue by limiting damage and dysfunction as cells age. They do not establish that increasing BLST would relieve back pain in humans, or that a CRISPR-based intervention could safely do so.

The research was led by Robby D. Bowles, an associate professor of biomedical engineering at the University of Utah. His team worked with researchers in orthopaedics, arthritis and other fields at the university, including collaborators at Huntsman Cancer Institute. The paper, by Lewis and colleagues, is titled “Znf865 (blst) a novel regulator of DNA damage and cell senescence in back pain” and was published in 2026.

At a glance
reportWhen: Published November 2026
The developmentA University of Utah study published in Aging Cell characterizes BLST’s role in spinal disc cells and reports effects from changing its levels in cell and animal models.

A Possible Target in Disc Aging

Spinal discs sit between the vertebrae and help the spine move. Damage and age-related changes in these structures are relevant to back pain, but the study does not show that BLST is the sole cause of disc degeneration or that changing its activity will prevent symptoms. Its contribution is a newly characterized biological mechanism that researchers can investigate further.

Bowles said the work supports the idea that DNA damage can drive back pain and that BLST may be regulated therapeutically. That is the researchers’ interpretation of findings from cells and animals; whether the mechanism translates to people remains unknown. For patients, the near-term importance is scientific rather than clinical: the findings may guide future studies, but do not change current care.

The team also points to potential relevance beyond spinal discs. Since BLST is expressed across tissues and is involved in DNA-damage responses, researchers say the mechanisms could inform studies of cancer and other diseases associated with DNA damage. Those possible applications remain research questions, not demonstrated benefits or treatments.

Products Worth Considering

Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale

Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale

Garmin Forerunner 265S Running Smartwatch, 42 mm, Whitestone/Neo Tropic

Garmin Forerunner 265S Running Smartwatch, 42 mm, Whitestone/Neo Tropic

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

As an affiliate, we earn on qualifying purchases.

How Researchers Tested BLST

The study is described by its authors as the first functional characterization of the ZNF865 gene and its protein, BLST. Researchers examined what happened when BLST was increased or decreased, using gene editing in human disc cells and experiments in rodents. This approach allowed them to compare cellular signs of damage with disc changes and pain-related behavior in animals.

The paper’s reported results span different experimental settings: restoration of BLST in human cells and reduction of its activity in rodents. These findings provide evidence about biological effects in those models, but they are not equivalent to a clinical trial. The source material does not report testing a BLST-targeting therapy in people or measuring whether it improves patient outcomes.

Back pain is a major source of disability. Bowles described it as the number-three leading cause of disability measured by disability-adjusted life years, behind cardiac disease and drug use disorders. The study offers a potential line of inquiry into disc-related mechanisms; it does not establish how much of back pain in the population is caused by BLST-related processes.

““This paper directly shows a novel understanding that DNA damage is a driver of back pain, and that we can regulate BLST therapeutically with CRISPR.””

— Robby D. Bowles, associate professor of biomedical engineering at the University of Utah

Human Benefits Remain Untested

The reported experiments do not show whether targeting BLST is safe or effective in people. Further preclinical work is needed before clinical trials, and the source does not provide a timeline for that research. It is also unclear whether CRISPR would be the appropriate or safe way to alter BLST in spinal discs, or what level and duration of activity might be beneficial.

The study’s findings do not establish that BLST changes can reverse disc aging in a living person, prevent back pain, or treat existing pain. The extent to which the same mechanisms apply to age-related cancers or neurodegenerative disease is also unresolved. Those wider possibilities are proposed areas for investigation, not findings confirmed by this study.

Preclinical Work Before Trials

Researchers say additional preclinical studies are needed to test whether manipulating BLST can be developed into a safe and effective approach. If that work supports further testing, clinical trials would eventually be needed to evaluate effects and risks in people. No such trial or treatment approval is reported in the source material.

Further research may also test whether BLST-related DNA repair mechanisms operate in other age-related diseases, including cancer. Until those studies provide clearer evidence, the findings should be viewed as an early research development rather than a basis for medical decisions. People with back pain should consult a qualified health professional about care.

Key Questions

What is BLST?

BLST, also called ZNF865, is a protein examined in the University of Utah study. Researchers report that its levels were lower in older and damaged spinal discs and that changing its activity affected disc cells and rodent models.

Did the study test a treatment in people?

No. The study used human disc cells and mouse and rat models, but it did not report a clinical trial. Safety and effectiveness in people remain unknown.

What happened when researchers changed BLST levels?

Restoring BLST production in human disc cells reduced signs of cellular aging and DNA damage. In rodents, reducing BLST activity was associated with disc degeneration and pain-related behaviors. These results come from experimental models, not treatment trials in patients.

Could BLST lead to a back-pain treatment?

The findings suggest a possible research direction, but no BLST-based back-pain treatment has been shown to be safe or effective. More preclinical work and, eventually, clinical trials would be needed.

Could the findings apply to cancer?

The researchers say BLST’s role in DNA damage may be relevant to cancer research. The study does not establish that targeting BLST prevents or treats cancer; that possibility requires separate investigation.

Source: news-medical.net

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Injuries Derailed Their Seasons. The Recovery Was Good Content.

Athletes’ injuries interrupted their seasons, but their recoveries generated significant media interest. The story highlights resilience and public fascination.

Hesse Reports Two Malaria Cases Near Frankfurt Airport

Two residents near Frankfurt Airport in Hesse have been diagnosed with malaria, according to DIE ZEIT. The cases are confirmed, raising health concerns in the region.

Cases of ‘explosive diarrhea’ infections spread in U.S., with major Midwest outbreak

Over 2,000 cases of cyclospora infections causing severe diarrhea have been reported across the U.S. Midwest, prompting health alerts and investigation efforts.

Health Sciences Surges In Global Coverage

Health sciences coverage has surged internationally, with 22 mentions in recent media analysis, highlighting increased global focus on health research and innovation.